long intergenic non-protein coding RNA 2245Genealiases: []
Q-omics provides the consensus-scored LINC02245 profile across patient tissues and cancer cell-line models. LINC02245 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, LINC02245 is differentially expressed in 8, with the highest sampling consensus in COAD. Additionally, LINC02245 RNA expression shows 16,475 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight BRCA, COAD, and GBM as cancer lineages where LINC02245 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC02245 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC02245 survival associations across molecular data types. LINC02245 RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC02245 RNA expression–survival associations across cancer types. High LINC02245 expression shows unfavorable associations in ACC, but favorable associations in BRCA, HNSC, BLCA, CESC and LUAD. The BRCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BRCA as the clearest survival context for LINC02245 RNA expression.
This table summarizes LINC02245 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for LINC02245. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC02245 shows lower tumor expression in COAD, BLCA and STAD and higher tumor expression in LUAD, BRCA and KIRC. The COAD box plot shows higher LINC02245 RNA expression in normal versus tumor tissue (log2 FC = −0.132, t-test p < 0.001).
This table shows molecular features associated with LINC02245 in patient tissues and cancer cell lines. In patient samples, LINC02245 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set.
